Customers who struggle to afford the $1,000-plus list price for weight-loss drugs Zepbound and Wegovy will have the option to buy now and pay later under a partnership announced Tuesday by ...

Zepbound is a glucagon-like peptide-1 (GLP-1) agonist drug with the active ingredient tirzepatide. It comes as a weekly injectable prescription weight loss medication that has two main functions ...

Zepbound generated $4.9 billion in global sales last year. Wegovy brought in nearly $8.8 billion (58.2 billlion Danish kroner). Access and affordability have limited wider use of the drugs.

Zepbound generated $4.9 billion in global sales last year. Wegovy brought in nearly $8.8 billion (58.2 billlion Danish kroner). Access and affordability have limited wider use of the drugs.

Researchers compared the safety and efficacy of tirzepatide (brand name Zepbound) and semaglutide (brand name Wegovy) in a 72-week clinical trial. The randomized, controlled trial — called ...

Some consumers are taking smaller than standard doses of GLP-1s—the popular class of weight-loss and diabetes drugs that include Ozempic, Wegovy, and Zepbound—or spacing out doses longer than ...

The organization plans to back GLP-1s like Wegovy and Zepbound to treat obesity in adults as part of a shift in addressing the global obesity epidemic, as reported by Reuters. In a memo ...